HealthKick Podcast: ASX biotech Dimerix gains momentum from involvement in multiple COVID-19 studies

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Nina Webster, CEO & managing director of Dimerix (ASX:DXB).

Dimerix (ASX:DXB) is a clinical stage biopharmaceutical company. The company develops and commercialises patient preferred pharmaceutical products for global markets using receptor technology to identify and develop drugs in areas with an unmet need.

Dimerix is currently building on its partnership with Sydney Uni to expand a global COVID-19 treatment study into Australia.

The company recently announced confirmation it has received Australian ethics and regulatory approval for the trial, named ACTION3.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!